51 related articles for article (PubMed ID: 8857232)
1. Clinical evaluation of human granulocyte colony-stimulating factor in chemotherapy for ovarian cancer.
Nagai N; Takehara K; Murakami T; Ohama K; Miyaoka S; Fujii T; Matsubayashi S
Hiroshima J Med Sci; 1995 Dec; 44(4):99-103. PubMed ID: 8857232
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
4. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
5. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
7. Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study.
Peters-Engl C; Medl M; Denison U; Sevelda P; Leodolter S; Petru E
Anticancer Res; 2001; 21(5):3701-6. PubMed ID: 11848547
[TBL] [Abstract][Full Text] [Related]
8. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
Kushner BH; Heller G; Kramer K; Cheung NK
Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of combination therapy with paclitaxel and carboplatin against postoperative small residual disease in patients with stage I c-IV ovarian cancer--KCOG 989 trial].
Nakata Y; Yamada T; Itoh R; Koishi K; Hiraoka K; Yamagami K; Itani Y; Toyoda S; Itoh K; Kimura T; Hosokawa K; Honjo H; Fujita H; Koshiba H; Hara Y; Tsuchiya H; Adachi S
Gan To Kagaku Ryoho; 2002 May; 29(5):717-22. PubMed ID: 12040675
[TBL] [Abstract][Full Text] [Related]
12. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
[TBL] [Abstract][Full Text] [Related]
15. [Mobilization of autologous peripheral blood stem cells by cytosine arabinoside combined with recombinant human granulocyte colony-stimulating factor].
Shi Y; Han X; He X; Yang J; Liu P
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(7):462-6. PubMed ID: 12133516
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
[TBL] [Abstract][Full Text] [Related]
18. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
Juweid ME; Blumenthal RD; Lew W; Hajjar G; Rubin AD; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
20. Timely withdrawal of G-CSF reduces the occurrence of thrombocytopenia during dose-dense chemotherapy.
Timmer-Bonte JN; de Mulder PH; Peer PG; Beex LV; Tjan-Heijnen VC
Breast Cancer Res Treat; 2005 Sep; 93(2):117-23. PubMed ID: 16187231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
